Talphera Makes Strategic Moves with FDA and Financing for NEPHRO CRRT Study Talphera, Inc. has reached an agreement with the FDA to significantly reduce its NEPHRO CRRT study size and announced a private financing commitment of up to $14.8 million to enhance clinical trials.

Talphera Makes Strategic Moves with FDA and Financing for NEPHRO CRRT Study #United_States #NEPHRO_CRRT #San_Mateo,_California #Talphera_Inc #FDA_Agreement